Thilo Schroeder News Today

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) – SVB Leerink decreased their Q2 2023 earnings per share estimates for Revolution Medicines in a report released on Monday, May 8th. SVB Leerink analyst J. Chang now forecasts that the company will post earnings of ($0.85) per share for the quarter, down from their prior forecast of […]

Revolution Medicines (NASDAQ:RVMD – Get Rating) posted its earnings results on Monday. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.12, Briefing.com reports. Revolution Medicines had a negative net margin of 744.36% and a negative return on equity of 41.68%. The business had revenue of […]

Revolution Medicines (NASDAQ:RVMD – Get Rating) is set to release its earnings data after the market closes on Monday, May 8th. Analysts expect Revolution Medicines to post earnings of ($0.84) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Revolution Medicines (NASDAQ:RVMD […]

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) – HC Wainwright raised their Q1 2023 earnings estimates for Revolution Medicines in a report released on Wednesday, April 12th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.78) per share for the quarter, up from their previous estimate of ($0.92). HC Wainwright currently […]

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target […]

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among […]

CRANBURY, N.J., Nov. 04, 2022 -- PMV Pharmaceuticals, Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53,... | November 4, 2022

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages […]

Investment analysts at Bank of America started coverage on shares of Revolution Medicines (NASDAQ:RVMD – Get Rating) in a report released on Friday, The Fly reports. The firm set a “neutral” rating on the stock. RVMD has been the topic of several other research reports. Stifel Nicolaus raised Revolution Medicines from a “hold” rating to […]

Revolution Medicines (NASDAQ:RVMD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. […]